Molecular analysis of a mammary analog secretory carcinoma in the upper lip Novel search for genetic and epigenetic abnormalities in MASC by Abe, Masanobu et al.
CASE REPORT – OPEN ACCESS
International Journal of Surgery Case Reports 9 (2015) 8–11
Contents lists available at ScienceDirect
International Journal of Surgery Case Reports
journa l homepage: www.caserepor ts .com
Molecular analysis of a mammary analog secretory carcinoma in the
upper lip
Novel search for genetic and epigenetic abnormalities in MASC
Masanobu Abea,b,∗,1, Ryoko Inakia,1, Yuki Kannoa, Kazuto Hoshia, Tsuyoshi Takatoa
a Department of Oral & Maxillofacial Surgery, University of Tokyo Hospital, Tokyo, Japan
b Division for Health Service Promotion, University of Tokyo, Tokyo, Japan
a r t i c l e i n f o
Article history:
Received 26 December 2014
Accepted 7 February 2015
Available online 11 February 2015
Keywords:
Mammary analog secretory carcinoma
MASC
ETV6-NTRK3 fusion gene
Salivary gland tumor
DNA methylation
Mutation
a b s t r a c t
INTRODUCTION: Mammary analog secretory carcinoma (MASC) is a newly described rare malignancy of
the salivary glands characterized by an ETS variant 6 (ETV6)–neurotrophic tyrosine kinase receptor type
3 (NTRK3) fusion gene (EN fusion gene).
PRESENTATION OF CASE: We present a case of MASC derived from the left upper lip in a 61-year-old
woman. ETV6 rearrangement was detected by ﬂuorescence in situ hybridization (FISH). The presence
of EN fusion transcripts was veriﬁed by reverse-transcriptase polymerase chain reaction (RT-PCR) and
sequencingof thePCRproducts.Accordingly, this tumorwasdiagnosedasMASC.Moreover,weperformed
mutation analysis of the 50 known cancer-related genes using next-generation sequencing. No mutation
of cancer-related genes was identiﬁed here. Subsequently, the methylation status in promoter region
of tumor-suppressor genes, RASSF1A and RARB2, was examined. Both genes have been reported to be
methylated in malignant salivary gland tumors, but they were found to be unmethylated.
DISCUSSION:Recent studieshavedemonstrated that distinct typesofmalignant salivary gland carcinomas
are driven by speciﬁc, highly recurrent genetic alterations. Detection of molecular abnormalities could
be powerful diagnostic tools in the ﬁeld of salivary gland tumors in near future.
CONCLUSION:Weexperienceda raremalignant salivaryglandcarcinoma,MASC.Wediagnosed this tumor
by molecular approach and subsequently tried to identify novel molecular abnormalities. Although no
novel molecular alteration except for EN fusion gene was identiﬁed, this result might represent the
favorable prognosis of patients with MASC.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
MASC is a recently described salivary gland carcinoma that
is characterized by its morphologic and molecular similarities to
breast secretory carcinoma (SC), which is a rare but distinct sub-
type of breast carcinoma, with a characteristic histomorphology
and generally favorable prognosis [1–4].
MASC is reported to be morphologically close to ACC in salivary
gland carcinoma. It can be distinguished from ACC by the absence
of zymogen granules, and by its strong S-100, vimentin, and
mammaglobin immunoexpression. However, the most deﬁnitive
characterization of diagnosis for MASC is a balanced chromosomal
translocation, t(12;15)(p13;q25), resulting in the formation of the
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EN fusion gene that encodes a chimeric oncoprotein tyrosin kinase
[3].
We encountered a salivary gland tumor that was suspected to
be MASC and tried to diagnose the tumor by immunostaining and
a molecular approach. Furthermore, genetic and epigenetic back-
ground except for EN gene have not yet been elucidated in MASC.
Accordingly, we looked for any genetic and/or epigenetic alter-
ations in this tumor.
2. Case report
A 61-year-old Japanese female presented in the department
of oral and maxillofacial surgery with a soft and tender mass in
the left upper lip (Fig. 1a). The major axis of the mass was 8mm.
She had been aware of the painless mass for 1 year. However, she
recently discovered bleeding from the mass, which brought her to
the hospital. A biopsywas performed and the pathologic evaluation
of the specimen identiﬁed that the tumor was analogous to ACC
with mammillary cellular proliferation. The tumor was composed
of tubular structures or papillary architecture, with eosinophilic
http://dx.doi.org/10.1016/j.ijscr.2015.02.011
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
CASE REPORT – OPEN ACCESS
M. Abe et al. / International Journal of Surgery Case Reports 9 (2015) 8–11 9
Fig. 1. Clinical and histopathological ﬁndings.
The arrowhead showed a soft and tender mass in the left upper lip (a). Microscopic ﬁndings are as follows (b–h). Hematoxylin-eosin staining showed that the tumor was
composed of tubular structures or papillary architecture, with eosinophilic secretory ﬂuid within the lumens of the tubules (b). Strong immunostaining was observed for the
S-100 protein (c), vimentin (d) and EMA (e). Weak immunostaining was observed for -SMA (f) and p63 (g). Strong immunoreactivity was observed for p53 (h).
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Fig. 2. Molecular ﬁndings.
(A) FISH analysis of ETV6 gene rearrangement using Vysis®LSI® ETV6 Break Apart
Rearrangement Probe (Abbott Molecular/Vysis). The arrowheads show the cells
which have ETV6 rearrangement. A yellow (red/green fusion) signal indicates an
intact chromosome while separate red and green signals indicate an ETV6 gene
break.
(B) Expression of ETV6-NTRK3 fusion transcript in the MASC and noncancerous oral
mucosa by RT-PCR. (1) DNA marker; (2) noncancerous oral mucosa; (3) cancerous
lesion; (4) distilled water.
(C) Validation of ETV6-NTRK3 fusion transcript by direct sequencing. Arrows show
translocation breakpoint.
(D) Methylation analysis of promoter CGIs of RASSF1A and RARB2 in MASC and non-
cancerous specimens. M, primers speciﬁc to methylated DNA; Alu, primers that
target the Alu repeat sequence were used as a control of the amount of bisulﬁte-
treated DNA. Promoter CGIs of RASSF1A and RARB2 were unmethylated in both the
non-cancerous specimen (1) and MASC (2). Fully methylated DNA was prepared by
methylating genomic DNA using SssI-methylase (3). Fully unmethylated DNA was
prepared by amplifying genomic DNA with ø29 DNA polymerase (4).
secretory ﬂuid within the lumens of the tubules (Fig. 1b). Immuno-
histochemically, tumor cells showed diffusely positive staining of
the S-100 protein, vimentin, EMA and p53 (Fig. 1c–e,h). On the
other hand, tumor cells show negative staining of -SMA and p63
(Fig. 1f,g).
The chromosomal translocation, t(12;15)(p13;q25), was ana-
lyzed by ﬂuorescence in situ hybridization (FISH) using Vysis®LSI®
ETV6 (TEL) (12p13) Dual Color, Break Apart Rearrangement Probe
(Abbott Molecular/Vysis, Des Plaines, IA) in formalin-ﬁxed and
parafﬁn-embedded tissue.Obvious rearrangementof theETV6gene
was detected in the cancerous lesion (Fig. 2A). The ETV6 rearrange-
ment was identiﬁed in 30% of the tumor cells (data not shown).
The presence of EN fusion transcripts in this tumor was analyzed
by RT-PCR and sequencing of the PCR products. RT-PCR revealed
the EN fusion transcripts (Fig. 2B). Furthermore, the PCR products
were cloned to T-Vector pMD20 (Takara Bio Inc., Shiga, Japan), and
the sequences of the PCR products were determined. The result
matched the sequencing of EN fusion transcripts (Fig. 2C). Accord-
ingly, this tumor was in full accordance with the concept of MASC
[2].
Mutational analysis of known cancer-related genes was per-
formed using Ion AmpliSeqTM Cancer Hotspot Panel v2 (Ion
Torrent), which covers 2800 COSMIC mutations from 50 cancer
genes, MPL, NRAS, ALK, IDH1, ERBB4, VHL, MLH1, CTNNB1, PIK3CA,
FGFR3, PDGFRA, KIT, KDR, FBXW7, APC, CSF1R, NPM1, EGFR, MET,
SMO, BRAF, EZH2, FGFR1, JAK2, CDKN2A, GNAQ, ABL1, NOTCH1, RET,
PTEN, FGFR2,HRAS,ATM,KRAS, PTPN11,HNF1A, LT3,RB1,AKT1, IDH2,
CDH1, TP53, ERBB2, SMAD4, STK11, GNA11, JAK3, SRC, GNAS and
SMARCB1, by next-generation sequencing, using the Ion Torrent
Personal Genome Machine (PGMTM) sequencer (Ion Torrent). The
result showed that theMASC specimendidnot harbor these genetic
abnormalities (data not shown).
Abnormalities of DNA methylation have not been analyzed yet
in MASC. However, the methylation status of promoter CGIs of
RASSF1A and RARB2, [5] whose aberrant methylation has been
reported in malignant salivary gland tumors, [6] were determined
by methylation-speciﬁc PCR (MSP) in MASC and a non-cancerous
specimens. Sodiumbisulﬁte treatmentwas performed as described
previously. For MSP, 1l of the solution was used for PCR with
primers speciﬁc to methylated DNA sequences (M) or primers for
Alu repeat sequences as a control of the amount of bisulﬁte-treated
DNA [7,8]. FullymethylatedDNAand fully unmethylatedDNAwere
prepared respectively according to the previous report [5]. The
results showed no methylation of the promoter CpG islands (CGIs)
of the two tumor-suppressor genes, RASSF1A and RARB2, in either
the MASC or non-cancerous specimen (Fig. 2D).
3. Discussion
MASC is a recently described salivary gland carcinoma charac-
terized by the EN fusion gene encoding a chimeric tyrosine kinase.
However, the molecular details of this rare tumor have not been
elucidated yet. Here, FISH analysis demonstrated that this sali-
vary gland tumor was positive for ETV6 disruption. Accordingly, we
coulddiagnose this tumor as aMASCand subsequently searched for
unknown genetic and epigenetic abnormalities in this MASC case.
The most common primary site of MASC is the parotid gland,
followed by the oral cavity, submandibular gland and accessory
parotid gland. In the oral cavity, the lip, soft palate, and buccal
mucosa are the most commonly affected subsites [2]. Recently,
it was reported that most non-parotid ACCs could be MASCs [9].
The mean size of MASC tumors was reported to be 21mm (range
7–55mm) [2]. The size of the tumor in this case (major axis of the
mass) was 8mm, which is close to the smallest documented size of
this tumor [2,4].
MASC most often presents as a slow-growing, painless mass.
The important differential diagnostic considerations of MASC
are low-grade adenocarcinoma not otherwise speciﬁed (NOS),
cystadenocarcinoma, and ACC. These tumors may share an over-
lapping morphology with MASC. Especially, MASC is known to be
morphologically close to ACC in salivary gland carcinomas and
characterizedby strong S-100proteinmammaglobin andvimentin,
whereas ACC is reported to have moderate or weak staining for S-
100 protein and vimentin, and negative staining for mammaglobin
[3]. In this case, the tumor cells showed relatively strong stain-
ing for S-100 protein and vimentin. Subsequently, MASC cells were
found positive for the glandular epithelial marker, EMA, and nega-
tive for the myoepithelial markers, -SMA and p63. Transcripts of
CASE REPORT – OPEN ACCESS
M. Abe et al. / International Journal of Surgery Case Reports 9 (2015) 8–11 11
a tumor-suppressor gene p53 were strongly stained in and around
the glandular epithelial cells. These resultswere in accordancewith
previous reports [4].
Mutations of the 50 known cancer-related genes were analyzed
using Ion AmpliSeqTM Cancer Hotspot Panel v2 and Ion Torrent
PGM sequencer. No mutation of cancer-related genes was iden-
tiﬁed in this analysis. The result of immunostaining demonstrated
overexpression of p53 in this MASC case; however, no mutation of
the p53 gene was detected. This result is in accordance with the
previous studies [4,9].
No methylation analysis has previously been performed in
MASC. Williams et al. demonstrated that RASSF1A and RARB2 were
highly methylated in malignant salivary gland tumors, but did not
examineMASC.RASSF1A is frequentlymethylated, especially inACC
and salivary duct carcinomas (SDC). RARB2 can be highly methy-
lated, especially inmucoepidermoidcarcinomas (MEC)andsalivary
duct carcinomas (SDC) [6]. In our analysis, no aberrant methyla-
tion of RASSF1A and RARB2 was observed in either the MASC or
non-cancerous specimen.
Recent studies have demonstrated that distinct types of malig-
nant salivary gland carcinomas are driven by speciﬁc, highly
recurrent genetic alterations. In addition to MASC, mucoepider-
moid carcinoma and hyalinizing clear cell carcinoma are driven by
fusion genes, CTRC1-MAML2 and EWSR1-ATF1, respectively. Poly-
morphous low-grade adenocarcinoma (PLGA) is driven by hot-spot
mutation of the PRKD1 gene [10].
Here,weexperienceda raremalignant salivaryglandcarcinoma,
MASC. We diagnosed this tumor by molecular approach and subse-
quently tried to identify novel molecular abnormalities. Although
no novel molecular alteration was identiﬁed in this tumor,
this result might represent the favorable prognosis of patients
with MASC.
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